Merck and Eisai announced today that KEYTRUDA®, an anti-PD-1 therapy, in combination with LENVIMA with respective clinical criteria and conditions for adult patients with advanced (not amenable to curativ...
also drew attention. In the obese animal model, HM15136 was twice as effective as currently available drugs in weight loss and shown significant body-weight reduction when administered in combination with...